Last reviewed · How we verify
Nicotine (2 mg)
Nicotine (2 mg) is a Nicotinic acetylcholine receptor agonist Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Smoking cessation aid, Reduction of nicotine withdrawal symptoms.
Nicotine binds to nicotinic acetylcholine receptors in the brain and peripheral nervous system, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation.
Nicotine (2 mg) is used in various interventions, including NRT Gum, to treat conditions such as smoking cessation and nicotine dependence. It is also studied in relation to smoking, vaping, and e-cig use, with its pharmacokinetic profile and safety evaluated in clinical trials like NCT01959607.
At a glance
| Generic name | Nicotine (2 mg) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Nicotinic acetylcholine receptor agonist |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Nicotine is an alkaloid that acts as an agonist at nicotinic acetylcholine receptors, mimicking the effects of acetylcholine. By delivering controlled doses of nicotine without the harmful combustion products of tobacco, it reduces the reinforcing effects of smoking and alleviates withdrawal symptoms such as irritability, anxiety, and difficulty concentrating. The 2 mg formulation is typically delivered via chewing gum and is designed for gradual dose reduction as part of a smoking cessation program.
Approved indications
- Smoking cessation aid
- Reduction of nicotine withdrawal symptoms
Common side effects
- Mouth and throat irritation
- Hiccups
- Dyspepsia
- Jaw soreness
- Nausea
- Headache
Key clinical trials
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Orexin s Role in the Neurobiology of Substance Use Disorder (NA)
- Defining Neurobiological Links Between Substance Use and Mental Illness (NA)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation (PHASE2, PHASE3)
- THRIVE in Sedated Gastrointestinal Endoscopy
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine (2 mg) CI brief — competitive landscape report
- Nicotine (2 mg) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Nicotine (2 mg)
What is Nicotine (2 mg)?
How does Nicotine (2 mg) work?
What is Nicotine (2 mg) used for?
Who makes Nicotine (2 mg)?
What drug class is Nicotine (2 mg) in?
What development phase is Nicotine (2 mg) in?
What are the side effects of Nicotine (2 mg)?
What does Nicotine (2 mg) target?
Related
- Drug class: All Nicotinic acetylcholine receptor agonist drugs
- Target: All drugs targeting Nicotinic acetylcholine receptors
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Addiction Medicine / Smoking Cessation
- Indication: Drugs for Smoking cessation aid
- Indication: Drugs for Reduction of nicotine withdrawal symptoms
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing